Publication | Closed Access

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Hematological MalignancyOncologyHematologyMyeloid NeoplasiaPharmacotherapyMedicineRadiation OncologyPhase 3Refractory Multiple MyelomaHealth Sciences